ArticleHistopathology2022
Secretory carcinoma of the salivary gland: a multi-institutional clinicopathologic study of 90 cases with emphasis on grading and prognostic factors.
Article in Histopathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 23 citations in OpenAlex.
- Article
- Secretory carcinoma in the parotid gland: A case report.Molecular and clinical oncology · 2026Article
- One case of facial salivary gland secretory carcinoma and a literature review.International journal of surgery case reports · 2026Article
- Clinicopathological characteristics, incidence trends, and prognostic factors of salivary gland secretory carcinoma: a SEER database analysis (2011-2021).European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2026Article
- Intraductal carcinoma of the parotid gland, mixed intercalated duct and oncocytic subtype with mucinous and serous acinar differentiation: cytologic and histologic features of a novel morphology.Virchows Archiv : an international journal of pathology · 2026Article
- Conversion Surgery After Administration of a TRK Inhibitor for Unresectable Parotid Gland Secretory Carcinoma.Head & neck · 2025Article
- Expanding the histologic spectrum of thyroid neoplasms with NTRK1/2/3 or ALK translocation: a single-center retrospective study of 82 cases.Virchows Archiv : an international journal of pathology · 2025Article
- Comprehensive Clinicopathologic, Morphologic, and Molecular Evaluation and Outcomes in Polymorphous Adenocarcinoma Tumors With Applicability of a 2-Tiered Grading System.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2025Article
- Histologic characteristics and predictors of outcome in epithelial-myoepithelial carcinoma (EMC) of salivary gland: a multi-center study of 75 cases.Virchows Archiv : an international journal of pathology · 2025Article
- Nodal Metastasis in Low Grade Salivary Gland Carcinoma: A Retrospective Analysis of Incidence, Histologic Spectrum and Outcome.Head and neck pathology · 2025Article
- Clinicopathologic characterization of secretory carcinoma of salivary gland.World journal of surgical oncology · 2024Article
- Secretory Carcinoma of the Thyroid: A Case Report and Update of Literature.Head and neck pathology · 2024Review
- ETV6 Molecular Heterogeneity in Salivary Secretory Carcinoma: A Case Series Report and Literature Review.Head and neck pathology · 2024Review
- Salivary Secretory Carcinoma in a Patient with Immature Ovary Teratoma.Iranian journal of otorhinolaryngology · 2024Article
- Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors.Contemporary oncology (Poznan, Poland) · 2023Article
- The evolving landscape of salivary gland tumors.CA: a cancer journal for cliniciansReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 1 country.
Funding
Abstract
Secretory carcinoma (SC) is a rare form of salivary carcinoma that was first described in 2010 and is characterized by ETV6::NTRK3 fusion in most cases. In this large retrospective study, we aimed to identify adverse clinicopathologic factors and propose a prognostically relevant grading scheme for SC.
methodsA detailed clinicopathologic review was conducted on 90 SCs from the major and minor salivary glands.
resultsThe median age at presentation was 50 years (range: 7-93). Sixty-nine (77%) tumours originated from major salivary glands, whereas the remaining 21 involved minor salivary glands.Six cases (7%) had cervical nodal metastasis. Only lymphovascular invasion (LVI) was associated with a risk of nodal metastasis (P < 0.05). The 5-year disease-specific survival and disease-free survival (DFS) were 98% and 87%, respectively. On univariate survival analysis, adverse prognostic factors associated with decreased DFS included minor salivary gland origin, atypical mitosis, high mitotic index, high-grade transformation (HGT), necrosis, nuclear pleomorphism, infiltrative tumour border, fibrosis at the invasive front, LVI, positive margin, and advanced pT stage (P < 0.05). When adjusted for pT stage and margin status, mitotic index, LVI, nuclear pleomorphism, and HGT remained as independent prognostic factors.
conclusionWe therefore propose a two-tiered grading system for SC. The low-grade SC is defined as those with <5 mitoses /10 high-power fields and no tumour necrosis, and high-grade SC as those with ≥5 mitoses /10 high-power fields and/or necrosis. This proposed grading system can be useful to risk stratify patients with SC for appropriate clinical management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.